In vivo anti-FAP CAR T therapy reduces fibrosis and restores liver homeostasis in metabolic dysfunction-associated steatohepatitis
Chittampalli N. Yashaswini(Icahn School of Medicine at Mount Sinai), Scott L. Friedman(Icahn School of Medicine at Mount Sinai), Tyler E. Papp(Translational Therapeutics (United States)), Kenneth Li(Icahn School of Medicine at Mount Sinai), Adi Lightstone(Pharmanest (Sweden)), Bruno Cogliati(Universidade de São Paulo), Tran To(Icahn School of Medicine at Mount Sinai), Joel G. Rurik(Karolinska Institutet), Tianyue Qin(Icahn School of Medicine at Mount Sinai), Jonathan A. Epstein(University of Pennsylvania), Raisa Rasul(Pharmanest (Sweden)), Hamideh Parhiz(Translational Therapeutics (United States)), Haig Aghajanian(Therapeutics Clinical Research), Shuang Wang(Icahn School of Medicine at Mount Sinai), Li Chen(Southern University of Science and Technology), Thomas Williamson(California Institute for Regenerative Medicine)
Cited by 12
Related Papers
Molecular Regulation of Hepatic Fibrosis, an Integrated Cellular Response to Tissue Injury
|Journal of Biological Chemistry|2000|2.1k
Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma
|New England Journal of Medicine|2008|1.3k
CAR T Cells Produced in vivo to Treat Cardiac Injury
|HAL (Le Centre pour la Communication Scientifique Directe)|2023|940
Targeting cardiac fibrosis with engineered T cells
|Nature|2019|799